Welcome to InfiCure Bio

InfiCure Bio is a life science company focusing on preclinical development and validation of drugs that target chronic inflammatory and fibrotic conditions.

Based on a panel of in vivo models for these conditions including a proprietary model for chronic inflammation and fibrosis, we offer effect tests of anti-inflammatory and anti-fibrotic drugs.

Founded on extensive experience and expertise in immunology, inflammation and fibrosis research, InfiCure Bio offers a proficient and flexible processing of drug validation projects in this area.

News

Local investors believe in InfiCure Bio

PartnerInvest Norr and Nordic Light Capital are local investors investing in InfiCure Bio. This is a great opportunity for InfiCure which makes it possible for the company to go global and expand its business. Read [...]

Come talk to us at NLSDays in Malmö

InfiCure Bio is present at NLSDays 2017 in Malmö on September 13th-14th. Take the chance to come and talk to us about our amazing N-IF model and other models currently in our pipeline. NLSDays is an [...]

InfiCure Bio in New York

InfiCure Bio was one of eight Nordic companies presenting at the 29th Seed Forum in New York on Wednesday June 7th. Last Minute Brief was held at Nordic Innovation House, WeWork Grand Central, on Tuesday June [...]

Preparation for meeting in New York

InfiCure Bio is one of 9 Nordic companies which will meet with American investors in New York on 7th of June. The three Swedish companies are InfiCure Bio, Smartster and Poseidon. Yesterday, the Swedish companies met at [...]